Join the club for FREE to access the whole archive and other member benefits.

Deep Longevity

AI to track the rate of ageing at the molecular, cellular, tissue, organ, system, physiological, and psychological levels

Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels.

It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes.

Deep Longevity developed Longevity as a Service (LaaS) solution to integrate multiple deep biomarkers of aging dubbed “deep aging clocks” to provide a universal multifactorial measure of human biological age.

Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from ETP Ventures, Human Longevity and Performance Impact Venture Fund, among others.

Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers.

Visit website: https://deeplongevity.com/

Details last updated 17-Jul-2020

Mentioned in this Resource

Human Longevity

Health Intelligence Company

Insilico Medicine

Biotechnology company that uses artificial intelligence to develop new drugs and for aging research

Deep Longevity is also referenced in the following:

ARDD 2021 - 8th Aging Research and Drug Discovery Meeting

31-Aug-2021 to 03-Sep-2021

Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.